LY-307174
A detailed overview of the compound LY-307174
LY-307174 is a chemical compound that has been studied for its potential effects on the central nervous system. It is primarily known for its role as a selective agonist of the metabotropic glutamate receptor subtype 2 (mGluR2). This receptor is part of the larger family of glutamate receptors, which are critical for synaptic transmission and plasticity in the brain.
Pharmacology[edit | edit source]
LY-307174 acts as a selective agonist at the mGluR2 receptor, which is a G-protein coupled receptor (GPCR) involved in modulating neurotransmission. Activation of mGluR2 has been shown to have various effects, including the inhibition of the release of excitatory neurotransmitters such as glutamate. This can lead to a reduction in neuronal excitability and has potential therapeutic implications for conditions characterized by excessive excitatory neurotransmission, such as epilepsy and anxiety disorders.
Mechanism of Action[edit | edit source]
The mechanism of action of LY-307174 involves binding to the mGluR2 receptor, which is predominantly located presynaptically. Upon activation, mGluR2 receptors inhibit adenylate cyclase activity, leading to a decrease in the production of cyclic AMP (cAMP). This results in the modulation of ion channels and a reduction in the release of glutamate from presynaptic neurons.
Research and Development[edit | edit source]
Research on LY-307174 has primarily focused on its potential as a therapeutic agent for neurological and psychiatric disorders. Preclinical studies have demonstrated its efficacy in animal models of anxiety and depression, suggesting that mGluR2 agonists like LY-307174 could be beneficial in treating these conditions. However, further research is needed to fully understand its pharmacokinetics, safety profile, and efficacy in humans.
Potential Therapeutic Applications[edit | edit source]
The potential therapeutic applications of LY-307174 include:
- Anxiety disorders: By reducing excessive glutamatergic activity, LY-307174 may help alleviate symptoms of anxiety.
- Depression: Modulation of glutamate transmission has been implicated in the pathophysiology of depression, and mGluR2 agonists may offer a novel approach to treatment.
- Schizophrenia: Some studies suggest that mGluR2 agonists could help in managing symptoms of schizophrenia, particularly those related to glutamatergic dysfunction.
Safety and Side Effects[edit | edit source]
As with any investigational drug, the safety and side effect profile of LY-307174 is not fully established. Preclinical studies have not reported significant adverse effects, but comprehensive clinical trials are necessary to determine its safety in humans.
Also see[edit | edit source]
- Metabotropic glutamate receptor
- Glutamate receptor
- G-protein coupled receptor
- Neurotransmission
- Anxiety disorder
- Depression (mood)
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
